{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:38:20Z","timestamp":1780403900566,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009169","name":"Assiut University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009169","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy with different molecular and genetic alterations. CD155 is expressed on myeloid cells and serves as a recognition molecule for natural killer (NK) cells to induce cytotoxicity. This study aimed to assess the prognostic and predictive value of CD155 in patients with AML.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We studied the expression of CD155 via flow cytometry in 93 AML patients at initial diagnosis at the Medical Oncology Department, South Egypt Cancer Institute (SECI), Egypt.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Flow cytometry revealed that a mean fluorescence intensity ratio (MFIR) \u22652.68 was associated with high CD155 expression. This criterion was met in 62 patients (66.7%). High expression was associated with a worse composite complete remission (CRc) rate than low expression (29.0 vs. 54.8%; <jats:italic>P<\/jats:italic>\u2009=\u20090.015). High CD155 expression had significantly shorter relapse-free survival (RFS), with a median of 1.68 (95% CI 0.92\u20132.43) months (<jats:italic>P<\/jats:italic>\u2009=\u20090.015), and overall survival (OS), with a median of 1.68 (95% CI 0.74\u20132.88) months (<jats:italic>P<\/jats:italic>\u2009=\u20090.041).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>High expression of CD155 in adult patients with AML is associated with a lower CRc, shorter RFS, and OS. It could be included within the predictive and prognostic panels.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12672-025-02665-2","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T05:58:00Z","timestamp":1748066280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CD155 as a prognostic and predictive biomarker in acute myeloid leukemia"],"prefix":"10.1007","volume":"16","author":[{"given":"Ashraf Zeidan","family":"Abdalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah Mabrouk","family":"Khallaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa Mohammed","family":"Zahran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal Adel","family":"Rayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Refaat Abd","family":"Elzaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"issue":"2","key":"2665_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2019001239","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135(2):85\u201396. https:\/\/doi.org\/10.1182\/blood.2019001239.","journal-title":"Blood"},{"issue":"6","key":"2665_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5603\/ahp.102572","volume":"55","author":"K Bieli\u0144ski","year":"2024","unstructured":"Bieli\u0144ski K, Pu\u0142a B, Bo\u0142kun \u0141. Checkpoint inhibitors as potential therapeutics in acute myeloid leukemia. Acta Haematol Pol. 2024;55(6):343\u201353. https:\/\/doi.org\/10.5603\/ahp.102572.","journal-title":"Acta Haematol Pol"},{"issue":"1","key":"2665_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41423-018-0168-y","volume":"16","author":"P Kucan Brlic","year":"2019","unstructured":"Kucan Brlic P, Lenac Rovis T, Cinamon G, Tsukerman P, Mandelboim O, Jonjic S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol. 2019;16(1):40\u201352. https:\/\/doi.org\/10.1038\/s41423-018-0168-y.","journal-title":"Cell Mol Immunol"},{"key":"2665_CR4","doi-asserted-by":"publisher","first-page":"105763","DOI":"10.1016\/j.intimp.2019.105763","volume":"75","author":"L Fang","year":"2019","unstructured":"Fang L, Zhao F, Iwanowycz S, Wang J, Yin S, Wang Y, et al. Anticancer activity of emodin is associated with downregulation of CD155. Int Immunopharmacol. 2019;75:105763. https:\/\/doi.org\/10.1016\/j.intimp.2019.105763.","journal-title":"Int Immunopharmacol"},{"key":"2665_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.semcancer.2019.11.013","volume":"65","author":"JS O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell JS, Madore J, Li XY, Smyth MJ. Tumor intrinsic and extrinsic immune functions of CD155. Semin Cancer Biol. 2020;65:189\u201396. https:\/\/doi.org\/10.1016\/j.semcancer.2019.11.013.","journal-title":"Semin Cancer Biol"},{"key":"2665_CR6","doi-asserted-by":"publisher","unstructured":"Deuss FA, Watson GM, Fu Z, Rossjohn J, Berry R. Structural basis for CD96 immune receptor recognition of nectin-like protein-5, CD155. Structure. 2019;27(2):219\u201328.e3. https:\/\/doi.org\/10.1016\/j.str.2018.10.023","DOI":"10.1016\/j.str.2018.10.023"},{"issue":"6","key":"2665_CR7","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3892\/ol.2013.1280","volume":"5","author":"S Atsumi","year":"2013","unstructured":"Atsumi S, Matsumine A, Toyoda H, Niimi R, Iino T, Sudo A. Prognostic significance of CD155 mRNA expression in soft tissue sarcomas. Oncol Lett. 2013;5(6):1771\u20136. https:\/\/doi.org\/10.3892\/ol.2013.1280.","journal-title":"Oncol Lett"},{"issue":"4","key":"2665_CR8","first-page":"2287","volume":"35","author":"S Nishiwada","year":"2015","unstructured":"Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, et al. Clinical significance of CD155 expression in human pancreatic cancer. Anticancer Res. 2015;35(4):2287\u201397.","journal-title":"Anticancer Res"},{"issue":"8","key":"2665_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrm2457","volume":"9","author":"Y Takai","year":"2008","unstructured":"Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 2008;9(8):603\u201315. https:\/\/doi.org\/10.1038\/nrm2457.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"24","key":"2665_CR10","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642\u20139. https:\/\/doi.org\/10.1200\/JCO.2003.04.036.","journal-title":"J Clin Oncol"},{"key":"2665_CR11","doi-asserted-by":"publisher","unstructured":"Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Sanchez-Correa B, Guerrero B, et al. Characterization of the DNAM-1, TIGIT and TACTILE axis on circulating NK, NKT-like and T cell subsets in patients with acute myeloid leukemia. Cancers. 2020;12(8). https:\/\/doi.org\/10.3390\/cancers12082171","DOI":"10.3390\/cancers12082171"},{"issue":"10","key":"2665_CR12","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/cas.13324","volume":"108","author":"J Gao","year":"2017","unstructured":"Gao J, Zheng Q, Xin N, Wang W, Zhao C. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 2017;108(10):1934\u20138. https:\/\/doi.org\/10.1111\/cas.13324.","journal-title":"Cancer Sci"},{"issue":"4","key":"2665_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4103\/ejh.ejh_5_21","volume":"45","author":"HS Mohamed","year":"2020","unstructured":"Mohamed HS, Azzazi MO, Hegab HA, Abdelallah NEHH. Analysis of poliovirus receptor, CD155, expression in patients with adult acute myeloid leukemia and its relation to clinical outcome. Egypt J Haematol. 2020;45(4):161\u20136. https:\/\/doi.org\/10.4103\/ejh.ejh_5_21.","journal-title":"Egypt J Haematol"},{"issue":"39","key":"2665_CR14","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1038\/s41388-018-0288-y","volume":"37","author":"H Stamm","year":"2018","unstructured":"Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, et al. Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene. 2018;37(39):5269\u201380. https:\/\/doi.org\/10.1038\/s41388-018-0288-y.","journal-title":"Oncogene"},{"issue":"23","key":"2665_CR15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V126.23.789.789","volume":"126","author":"H Stamm","year":"2015","unstructured":"Stamm H, Klingler F, Pende D, Vettorazzi E, Heuser M, Mock U, et al. Expression of novel immune checkpoint molecules PVR and PVRL2 confers a negative prognosis to patients with acute myeloid leukemia and their blockade augments T-cell mediated lysis of AML cells alone or in combination with the BiTE\u00ae antibody construct AMG 330. Blood. 2015;126(23):789. https:\/\/doi.org\/10.1182\/blood.V126.23.789.789.","journal-title":"Blood"},{"issue":"9\u201310","key":"2665_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s10495-018-1473-8","volume":"23","author":"J Gao","year":"2018","unstructured":"Gao J, Zheng Q, Shao Y, Wang W, Zhao C. CD155 downregulation synergizes with adriamycin to induce breast cancer cell apoptosis. Apoptosis. 2018;23(9\u201310):512\u201320. https:\/\/doi.org\/10.1007\/s10495-018-1473-8.","journal-title":"Apoptosis"},{"issue":"7","key":"2665_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4236\/jbm.2022.107003","volume":"10","author":"N El Menshawy","year":"2022","unstructured":"El Menshawy N, Selim T, Mohamed A, Ebrahiem MA, Farag NA, Saifeldein ER. Prognostic impact of poliovirus receptor expression (PVR) (CD155) in context to FLT3-ITD and NPM1 mutation status at Egyptian acute myeloid leukemia. J Biosci Med. 2022;10(7):38\u201352. https:\/\/doi.org\/10.4236\/jbm.2022.107003.","journal-title":"J Biosci Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02665-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02665-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02665-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T07:56:54Z","timestamp":1750665414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02665-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2665"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02665-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to correct the affiliations.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted following the protocol approved by the Ethical Committee rules at SECI, Assiut University (SECI-IRB IORG0006563\u2014Registration number: 545). Before enrollment in our study, the participants were asked to provide written informed consent. The study was registered on ClinicalTrials.gov (NCT number: NCT06369662) (on 1st July 2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details was obtained from the patient\/parent\/guardian\/ relative of the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"902"}}